A aplicabilidade das nanotecnologias no tratamento da Doença do Alzheimer

Jéssica Mendes Bonato; Gislaine Cardoso de Souza Fiaes; Samanta de Almeida Silva

doi:10.17765/2176-9192.2025v27e13619

Authors

Jéssica Mendes Bonato UniCesumar https://orcid.org/0000-0001-8175-5365
Gislaine Cardoso de Souza Fiaes UniCesumar https://orcid.org/0009-0001-6825-9946
Samanta de Almeida Silva UniCesumar https://orcid.org/0009-0006-1171-2988

DOI:

https://doi.org/10.17765/2176-9192.2025v27e13619

Keywords:

Alzheimer’s disease, Experimental models, Nanotechnology

Abstract

In the face of population aging, Alzheimer's disease (AD) has become increasingly prevalent. AD is a chronic and progressive disease with no cure, characterized mainly by the deterioration of cognitive processes, affecting elderly individuals, especially those over 65 years of age. In AD, the loss of nerve cells, i.e., the neurodegenerative process is related to the formation of neurotic plaques formed by the beta amyloid peptide (A?42) and neurofibrillary tangles. Faced with such a challenging pathology, few therapeutic strategies to alleviate symptoms and compensate for the neurological disorders suffered are in fact effective. Therefore, science has been investing in innovative ideas that bring expectations of progress in treatment, such as those seen by nanotechnology. To develop this article, the PubMed database was used through the National Institutes of Health (NIH) platform, from which 11 were selected for the construction of the study, in order to integrate theoretical concepts focused on innovative treatments adopted with the use of nanotechnology. These studies addressed different types of nanoparticles and transported molecules, with the aim of improving drug delivery or inhibiting amyloid aggregation. Current scientific evidence indicates that nanotechnologies present a promising window that may help in the treatment of AD.

Author Biographies

Jéssica Mendes Bonato, UniCesumar

Doutora e Mestre em Ciências Farmacêuticas pela Universidade Estadual de Maringá, na área de neuropsicofarmacologia (2017). Possui graduação em Biomedicina pela Universidade Estadual de Maringá (2014). Possui experiência na área de neuropsicofarmacologia, com ênfase em transtornos neurodegenerativos. Com experiência no ensino presencial e à distância nas disciplinas de anatomia e fisiologia humana e farmacologia. Atualmente é professora do ensino à distância Unicesumar.

Gislaine Cardoso de Souza Fiaes, UniCesumar

Mestre em Ciências Farmacêuticas pela Universidade Estadual de Maringá (UEM). Possui experiência na área de Neuropsicofarmacologia, com ênfase nos substratos neurais da ansiedade e na fisiopatologia dos transtornos de ansiedade generalizada, depressão e transtorno do pânico (2017). Especialização em Farmacologia Aplicada a Terapêutica pela Universidade Estadual de Maringá (UEM) (2019). Graduação em Farmácia pela UniCesumar (2013). Com experiência docente no ensino superior presencial e a distância, ministrando disciplinas, como: Anatomia Humana, Toxicologia, Parasitologia, Fundamentos de Farmacologia e Farmacologia Aplicada. Atualmente, exerce a função de coordenadora de curso do Núcleo de Educação a Distância da Unicesumar.

Samanta de Almeida Silva, UniCesumar

Graduanda do curso de Biomedicina (2022) no polo de Três Lagoas do Centro Universitário de Maringá (UniCesumar). Possui formação complementar com ênfase nas áreas de Ciências Biomédicas na Universidade Aberta do SUS(UNA-SUS), Universidade Federal do Maranhão(UFMA), Universidade Federal de Santa Catarina (UFSC), Fundação Oswaldo Cruz(Fiocruz) e Universidade Federal de Ciências da Saúde de Porto Alegre, além de cursos abrangentes com ênfase na área da engenharia, gestão de pessoas e áreas afins de ensino superior no Sest Senat (Serviço Social do Transporte e Serviço Nacional de Aprendizagem do Transporte), IFMS(Instituto Federal de Educação, Ciência e Tecnologia de Mato Grosso do Sul), Fundação Bradesco e USP- ESALQ(Universidade de São Paulo- Escola Superior de Agricultura "Luiz de Queiroz").Integrante do Grupo de Estudo no ano de 2023, Grupo de Pesquisa e participante do Programa Institucional de Bolsas de Iniciação Científica no ano de 2024 pelo Centro Universitário de Maringá.

References

BRAGHIROLLI, Iglesias D. Farmacologia aplicada. Porto Alegre: SAGAH, 2018. E-book. p.Capa. ISBN 9788595023116. Disponível em: https://app.minhabiblioteca.com.br/reader/books/9788595023116/. Acesso em: 14 mai. 2024.

BRIGGS, Robert et al. (2016). Drug treatments in Alzheimer's disease. Clinical medicine (London, England), 16(3), 247–253. 2016. DOI: 10.7861/clinmedicine.16-3-247.

CAMPISI, Judith et al. From discoveries in ageing research to therapeutics for healthy ageing. Nature, 571(7764), 183–192. 2019. 2019. DOI: 10.1038/s41586-019-1365-2.

CANO, Amanda et al. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. J Control Release. 2019 May 10;301:62-75. doi: 10.1016/j.jconrel.2019.03.010.

CUMMINGS, Jefrey. et al. Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. Journal of Alzheimer's disease: JAD, 67(3), 779–794. 2019. DOI: 10.3233/JAD-180766.

DE FALCO, Anna et al. Alzheimer’s disease: etiological hypotheses and treatment perpectives. Scielo Brasil, 39 (1), 63-80. 2016. DOI: 10.5935/0100-4042.20150152.

GUSTAVSSON, Anders et al. Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimer's & dementia: the journal of the Alzheimer's Association, 19(2), 658–670. 2023. DOI: 10.1002/alz.12694.

GU, Yutian et al. Tautargeting multifunctional nanocomposite based on tannic acid-metal for near-infrared fluorescence/magnetic resonance bimodal imaging-guided combinational therapy in Alzheimer's disease. Theranostics, 14(16), 6218–6235. 2024. DOI: 10.7150/thno.98462.

HAMPEL, Harald et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain: a journal of neurology, 141(7), 1917–1933. 2018. DOI: 10.1093/brain/awy132.

ISRAEL, Liron et al. A Combination of Tri-Leucine and Angiopep-2 Drives a Polyanionic Polymalic Acid Nanodrug Platform Across the Blood-Brain Barrier. ACS nano, 13(2), 1253–1271. 2019. DOI: 10.1021/acsnano.8b06437.

ISRAEL, Liron et al. ?-Amyloid targeting nanodrug for neuron-specific delivery of nucleic acids in Alzheimer's disease mouse models. Journal of controlled release : official journal of the Controlled Release Society, 361, 636–658. 2023. DOI: 10.1016/j.jconrel.2023.08.001.

JAVED, Ibrahim et al. Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy. Nature communications, 10(1), 3780. 2029. DOI: 10.1038/s41467-019-11762-0.

KHAN, Sahil et al. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease. Current neuropharmacology, 18(11), 1106–1125. 2020. DOI: 10.2174/1570159X18666200528142429.

LING, Tan S. et al. The Potential Benefits of Nanotechnology in Treating Alzheimer's Disease. BioMed research international, 5550938. 2021 DOI: 10.1155/2021/5550938.

LI, Yuhuan et al. Ultrasmall Molybdenum Disulfide Quantum Dots Cage Alzheimer's Amyloid Beta to Restore Membrane Fluidity. ACS applied materials & interfaces, 13(25), 29936–29948. 2021. DOI: 10.1021/acsami.1c06478.

Ministério da Saúde (GOV). Doença de Alzheimer. Disponível em: https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/a/alzheimer. Acesso em: 13 out. 2024.

MOREIRA, Gabriela et al. Atualizações sobre a doença de Alzheimer e seus estágios clínicos: Update on Alzheimer’s disease and its clinical stages. Brazilian Journal of Health Review, 5(6), 22020–22045. 2022. DOI: 10.34119/bjhrv5n6-016.

MORFILL, Corinne et al. Nanostars Carrying Multifunctional Neurotrophic Dendrimers Protect Neurons in Preclinical In Vitro Models of Neurodegenerative Disorders. ACS applied materials & interfaces, 14(42), 47445–47460. 2022. DOI: https://doi.org/10.1021/acsami.2c14220.

NAYAB, Dur E. et al. Nano biomaterials based strategies for enhanced brain targeting in the treatment of neurodegenerative diseases: an up-to-date perspective. Journal of nanobiotechnology, 21(1), 477. 2023. DOI: 10.1186/s12951-023-02250-1.

NELSON, Peter T et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. Journal of neuropathology and experimental neurology, 71(5), 362–381. 2012. DOI: 10.1097/NEN.0b013e31825018f7.

NIEMEYER, Guimarães. Envelhecimento populacional e a demanda por cuidados paliativos. Rio de Janeiro. Revista Eletrônica da Jornada de Pesquisa e Iniciação Científica. V. 02 (5º). 2019. ISSN: 2525-7293.

RIGBY, Brier et al. Evolutionary and genomic perspectives of brain aging and neurodegenerative diseases. Progress in brain research, 275, 165–215. 2023. DOI: 10.1016/bs.pbr.2022.10.004.

RUAN, Yutin et al. Highly sensitive Curcumin-conjugated nanotheranostic platform for detecting amyloid-beta plaques by magnetic resonance imaging and reversing cognitive deficits of Alzheimer's disease via NLRP3-inhibition. Journal of nanobiotechnology, 20(1), 322. 2022. DOI: https://doi.org/10.1186/s12951-022-01524-4.

SÁNCHEZ-LÓPEZ, Elena et al. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. Journal of nanobiotechnology, 16(1), 32. 2028. DOI: 10.1186/s12951-018-0356-z.

SANDERSON, Warren et al. Faster increases in human life expectancy could lead to slower population aging. PloS one, 10(4), e0121922. 2015. DOI: 10.1371/journal.pone.0121922.

Secretaria de Comunicação Social (GOV). Censo: número de idosos no Brasil cresceu 57,4% em 12 anos. Disponível em: https://www.gov.br/secom/pt-br/assuntos/noticias/2023/10/censo-2022-numero-de-idosos-na-populacao-do-pais-cresceu-57-4-em-12-anos#:~:text=Portanto%2C%20quanto%20maior%20o%20valor,%2C%20correspondendo%20a%2030%2C7. Acesso em: 18 out. 2024.

SILVA-ABREU, Marcelle et al. PPAR? agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies. International journal of nanomedicine, 13, 5577–5590. 2018. DOI: 10.2147/IJN.S171490.

SHIGUEMOTO, Gilve O. B.. Doença de Alzheimer e cuidador familiar principal: estudo da clientela do Programa do Medicamento de Dispensação Excepcional do município de São Carlos. (Dissertação de mestrado). Universidade Federal de São Carlos. São Paulo, Brasil.

TANG, Huayan et al. Graphene quantum dots obstruct the membrane axis of Alzheimer's amyloid beta. Physical chemistry chemical physics: PCCP, 24(1), 86–97. 2021. DOI: 10.1039/d1cp04246g.

TERRA, Newton L. Doença de Alzheimer: Jornada Geriatria. Pontifícia Universidade Católica de São Paulo. Disponível: https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.pucrs.br/eventos/wp-content/uploads/sites/73/2018/03/ALZHEIMER-2018.pdf&ved=2ahUKEwj454mqypWJAxVKpZUCHVygC08QFnoECC8QAQ&usg=AOvVaw1n_B_FkNi7OPteDG_naS6. Acesso em: 27 nov. 2024.

TOBBIN, Isabella. Doença de Alzheimer: uma revisão de literatura/ Alzheimer’s Disease: A Literature Review. Brazilian Journal of Health Review, 4(3), 14232–14244. 2021. DOI: 10.34119/bjhrv4n3-355.

VAKILINEAZHAD, Molood. et al. Application of Response Surface Method for Preparation, Optimization, and Characterization of Nicotinamide Loaded Solid Lipid Nanoparticles. Advanced pharmaceutical bulletin, 8(2), 245–256. 2018. DOI: 10.15171/apb.2018.029.

VILLAFLORES, Oliver B. et al. Curcuminoids and resveratrol as anti-Alzheimer agents. Taiwanese journal of obstetrics & gynecology, 51(4), 515–525. 2012. DOI: 10.1016/j.tjog.2012.09.005.

VIOLA, Kirstein et al. Amyloid ? oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta neuropathologica, 129(2), 183–206. 2015. DOI: 10.1007/s00401-015-1386-3.

WELLER, Jason et al. Current understanding of Alzheimer's disease diagnosis and treatment. F1000Research, 7, F1000 Faculty Rev-1161. 2018. DOI: 10.12688/f1000research.14506.1.

YARNS, Brandon et al. Pathophysiology of Alzheimer's Disease. The Psychiatric clinics of North America, 45(4), 663–676. 2022. DOI: 10.1016/j.psc.2022.07.003.